| abstract |
The present invention relates to the composition of PM01183 with several anticancer drugs, in particular selected from the group consisting of antitumor platinum complexes, antimetabolites, mitotic inhibitors, anticancer antibiotics, topoisomerase I and/or II inhibitors, proteasome Inhibitors, histone deacetylase inhibitors, nitrogen mustard alkylating agents, nitrosourea alkylating agents, atypical alkylating agents, estrogen antagonists, androgen antagonists, mTOR inhibitors, tyrosine kinases Inhibitors, and other anticancer drugs selected from the group consisting of aplidine, ET-743, PM02734 and PM00104, and the use of these combinations in the treatment of cancer. |